Display options
Cite
Elkader A, Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet. 2005;44(7):661-80doi: 10.2165/00003088-200544070-00001.
Elkader, A., & Sproule, B. (2005). Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clinical pharmacokinetics, 44(7), 661-80. https://doi.org/10.2165/00003088-200544070-00001
Elkader, Alexander, and Sproule, Beth. "Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence." Clinical pharmacokinetics vol. 44,7 (2005): 661-80. doi: https://doi.org/10.2165/00003088-200544070-00001
Elkader A, Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet. 2005;44(7):661-80. doi: 10.2165/00003088-200544070-00001. PMID: 15966752.
Copy Download .nbib Format: NLM
Share it on

Clin Pharmacokinet. 2005;44(7):661-80. doi: 10.2165/00003088-200544070-00001.

Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence.

Clinical pharmacokinetics

Alexander Elkader, Beth Sproule

Affiliations

  1. Centre for Addiction and Mental Health, Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.

PMID: 15966752 DOI: 10.2165/00003088-200544070-00001

Abstract

Buprenorphine is a semi-synthetic opioid derived from thebaine, a naturally occurring alkaloid of the opium poppy, Papaver somniferum. The pharmacology of buprenorphine is unique in that it is a partial agonist at the opioid mu receptor. Buprenorphine undergoes extensive first-pass metabolism and therefore has very low oral bioavailability; however, its bioavailability sublingually is extensive enough to make this a feasible route of administration for the treatment of opioid dependence. The mean time to maximum plasma concentration following sublingual administration is variable, ranging from 40 minutes to 3.5 hours. Buprenorphine has a large volume of distribution and is highly protein bound (96%). It is extensively metabolised by N-dealkylation to norbuprenorphine primarily through cytochrome P450 (CYP) 3A4. The terminal elimination half-life of buprenorphine is long and there is considerable variation in reported values (mean values ranging from 3 to 44 hours). Most of a dose of buprenorphine is eliminated in the faeces, with approximately 10-30% excreted in urine. Naloxone has been added to a sublingual formulation of buprenorphine to reduce the abuse liability of the product. The presence of naloxone does not appear to influence the pharmacokinetics of buprenorphine. Buprenorphine crosses the placenta during pregnancy and also crosses into breast milk. Buprenorphine dosage does not need to be significantly adjusted in patients with renal impairment; however, since CYP3A activity may be decreased in patients with severe chronic liver disease, it is possible that the metabolism of buprenorphine will be altered in these patients. Although there is limited evidence in the literature to date, drugs that are known to inhibit or induce CYP3A4 have the potential to diminish or enhance buprenorphine N-dealkylation. It appears that the interaction between buprenorphine and benzodiazepines is more likely to be a pharmacodynamic (additive or synergistic) than a pharmacokinetic interaction. The relationship between buprenorphine plasma concentration and response in the treatment of opioid dependence has not been well studied. The pharmacokinetic and pharmacodynamic properties of buprenorphine allow it to be a feasible option for substitution therapy in the treatment of opioid dependence.

References

  1. Neuropsychopharmacology. 2003 Nov;28(11):2000-9 - PubMed
  2. Drug Alcohol Depend. 2003 Oct 24;72(1):75-83 - PubMed
  3. Drug Alcohol Depend. 2004 Apr 9;74(1):37-43 - PubMed
  4. Drug Alcohol Depend. 2003 May 21;70(2 Suppl):S87-101 - PubMed
  5. Clin Chem. 1997 Dec;43(12):2292-302 - PubMed
  6. World J Gastroenterol. 2003 Feb;9(2):359-63 - PubMed
  7. J Child Adolesc Psychopharmacol. 1998;8(3):161-74 - PubMed
  8. Clin Pharmacol Ther. 1996 Jul;60(1):105-14 - PubMed
  9. Int J Clin Pract Suppl. 2003 Feb;(133):15-8; discussion 23-4 - PubMed
  10. Drug Alcohol Depend. 1998 Mar 1;50(1):1-8 - PubMed
  11. J Pharmacol Exp Ther. 2002 Nov;303(2):688-94 - PubMed
  12. Addiction. 1998 Sep;93(9):1385-92 - PubMed
  13. Acta Chir Hung. 1992-1993;33(3-4):367-74 - PubMed
  14. Eur J Biochem. 1997 Jul 15;247(2):625-34 - PubMed
  15. Arch Gen Psychiatry. 1978 Apr;35(4):501-16 - PubMed
  16. Drug Alcohol Depend. 2000 Dec 22;61(1):85-94 - PubMed
  17. J Forensic Sci. 2000 Jan;45(1):226-8 - PubMed
  18. Clin Pharmacol Ther. 1999 Sep;66(3):306-14 - PubMed
  19. Biol Psychiatry. 1997 Jun 1;41(11):1095-101 - PubMed
  20. Neuropsychopharmacology. 2000 Sep;23 (3):326-34 - PubMed
  21. Am J Psychiatry. 2000 Jul;157(7):1164-6 - PubMed
  22. Anal Biochem. 2002 Jul 1;306(1):31-9 - PubMed
  23. J Anal Toxicol. 1996 Oct;20(6):369-78 - PubMed
  24. Addiction. 2001 Jun;96(6):823-34 - PubMed
  25. Clin Pharmacokinet. 2004;43(5):329-40 - PubMed
  26. J Subst Abuse Treat. 2003 Apr;24(3):217-20 - PubMed
  27. N Engl J Med. 2000 Nov 2;343(18):1290-7 - PubMed
  28. Addiction. 2003 Apr;98(4):441-52 - PubMed
  29. Forensic Sci Int. 2001 Sep 15;121(1-2):65-9 - PubMed
  30. Addiction. 1998 Apr;93(4):549-59 - PubMed
  31. Addiction. 1998 Apr;93(4):475-86 - PubMed
  32. Hepatology. 1995 Jan;21(1):120-8 - PubMed
  33. Am J Addict. 2000 Summer;9(3):265-9 - PubMed
  34. Drug Alcohol Depend. 2001 Mar 1;62(1):97-104 - PubMed
  35. Clin Pharmacol Ther. 1988 Sep;44(3):335-42 - PubMed
  36. JAMA. 1990 Nov 21;264(19):2511-8 - PubMed
  37. Drug Alcohol Depend. 2001 Jun 1;63(1):97-103 - PubMed
  38. Addiction. 1999 Sep;94(9):1337-47 - PubMed
  39. Drug Metab Dispos. 1998 Mar;26(3):257-60 - PubMed
  40. Drug Metab Dispos. 1984 Sep-Oct;12(5):577-81 - PubMed
  41. Psychopharmacology (Berl). 1999 Jan;141(1):37-46 - PubMed
  42. Clin Pharmacol Ther. 1980 Nov;28(5):667-72 - PubMed
  43. Biol Psychiatry. 1993 Jul 1-15;34(1-2):66-74 - PubMed
  44. Br J Clin Pharmacol. 1982 May;13(5):665-73 - PubMed
  45. J Clin Pharmacol. 1997 Jan;37(1):31-7 - PubMed
  46. Am J Psychiatry. 1994 Jul;151(7):1025-30 - PubMed
  47. Clin Pharmacol Ther. 1997 Nov;62(5):569-71 - PubMed
  48. Anesthesiology. 1966 Sep-Oct;27(5):654-61 - PubMed
  49. J Chromatogr. 1985 Feb 27;338(1):89-98 - PubMed
  50. Int J Clin Pract Suppl. 2003 Feb;(133):3-8; discussion 23-4 - PubMed
  51. Pharm Res. 1996 Oct;13(10 ):1519-23 - PubMed
  52. Xenobiotica. 1981 Mar;11(3):189-96 - PubMed
  53. Life Sci. 1997;60(22):1953-64 - PubMed
  54. CMAJ. 2001 Mar 20;164(6):767-73 - PubMed
  55. Clin Pharmacol Ther. 1999 Jun;65(6):685-94 - PubMed
  56. Clin Pharmacol Ther. 1994 May;55(5):569-80 - PubMed
  57. Am J Public Health. 1996 May;86(5):642-54 - PubMed
  58. Anaesthesia. 1985 Sep;40(9):914 - PubMed
  59. Drug Alcohol Depend. 2003 Apr 1;69(3):317-22 - PubMed
  60. Eur J Public Health. 2001 Dec;11(4):425-30 - PubMed
  61. J Pharmacol Exp Ther. 2002 Nov;303(2):695-703 - PubMed
  62. Drug Alcohol Depend. 1995 Nov;40(1):17-25 - PubMed
  63. J Pharmacol Exp Ther. 1995 Feb;272(2):505-10 - PubMed
  64. Drug Alcohol Depend. 1999 Aug 2;56(1):55-60 - PubMed
  65. Drug Alcohol Depend. 1992 Aug;30(3):263-74 - PubMed
  66. NIDA Res Monogr. 1990;105:569 - PubMed
  67. J Clin Psychopharmacol. 1992 Dec;12(6):397-402 - PubMed
  68. Psychopharmacology (Berl). 1988;94(4):484-90 - PubMed
  69. J Clin Pharmacol. 1999 Jun;39(6):619-23 - PubMed
  70. Drug Alcohol Depend. 1990 Feb;25(1):27-34 - PubMed
  71. Life Sci. 2000 Feb 25;66(14):1293-8 - PubMed
  72. Drug Metab Dispos. 2001 Apr;29(4 Pt 1):460-5 - PubMed
  73. J Anal Toxicol. 1996 Jul-Aug;20(4):229-35 - PubMed
  74. J Anal Toxicol. 1998 Oct;22(6):430-4 - PubMed
  75. Eur J Clin Pharmacol. 1980 Oct;18(4):339-45 - PubMed
  76. Br J Anaesth. 1990 Mar;64(3):276-82 - PubMed
  77. JAMA. 2001 Jan 3;285(1):45 - PubMed
  78. Br J Clin Pharmacol. 1981 Aug;12(2):117-22 - PubMed
  79. Drug Metab Dispos. 1998 Aug;26(8):818-21 - PubMed
  80. Psychopharmacology (Berl). 2001 Mar;154(3):230-42 - PubMed
  81. Fundam Clin Pharmacol. 1998;12(2):194-9 - PubMed
  82. Biol Pharm Bull. 2002 May;25(5):682-5 - PubMed

Substances

MeSH terms

Publication Types